156 related articles for article (PubMed ID: 32536241)
1. Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review.
Achard V; Bottero M; Rouzaud M; Lancia A; Scorsetti M; Filippi AR; Franzese C; Jereczek-Fossa BA; Ingrosso G; Ost P; Zilli T
Acta Oncol; 2020 Oct; 59(10):1224-1234. PubMed ID: 32536241
[TBL] [Abstract][Full Text] [Related]
2. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
[TBL] [Abstract][Full Text] [Related]
3. Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.
Tran S; Jorcano S; Falco T; Lamanna G; Miralbell R; Zilli T
Am J Clin Oncol; 2018 Oct; 41(10):960-962. PubMed ID: 29315174
[TBL] [Abstract][Full Text] [Related]
4. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy in nodal oligorecurrent prostate cancer.
Pinkawa M; Aebersold DM; Böhmer D; Flentje M; Ghadjar P; Schmidt-Hegemann NS; Höcht S; Hölscher T; Müller AC; Niehoff P; Sedlmayer F; Wolf F; Zamboglou C; Zips D; Wiegel T
Strahlenther Onkol; 2021 Jul; 197(7):575-580. PubMed ID: 33914101
[TBL] [Abstract][Full Text] [Related]
6. Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.
Ingrosso G; Mariucci C; Tenti MV; Bini V; Alì E; Saldi S; Palumbo I; Bellavita R; Aristei C
Clin Transl Oncol; 2020 Dec; 22(12):2236-2243. PubMed ID: 32418156
[TBL] [Abstract][Full Text] [Related]
7. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
[TBL] [Abstract][Full Text] [Related]
8. Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159).
Marvaso G; Ciardo D; Corrao G; Gandini S; Fodor C; Zerini D; Rojas DP; Augugliaro M; Bonizzi G; Pece S; Cattani F; Mazzocco K; Mistretta FA; Musi G; Alessi S; Petralia G; Pravettoni G; De Cobelli O; Di Fiore PP; Viale G; Orecchia R; Jereczek-Fossa BA
BMC Cancer; 2019 Sep; 19(1):903. PubMed ID: 31500605
[TBL] [Abstract][Full Text] [Related]
9. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.
Fodor A; Lancia A; Ceci F; Picchio M; Hoyer M; Jereczek-Fossa BA; Ost P; Castellucci P; Incerti E; Di Muzio N; Ingrosso G
World J Urol; 2019 Dec; 37(12):2607-2613. PubMed ID: 29752513
[TBL] [Abstract][Full Text] [Related]
10. Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy.
Gawish A; Walke M; Röllich B; Ochel HJ; Brunner TB
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3937-3949. PubMed ID: 36029331
[TBL] [Abstract][Full Text] [Related]
11. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost P; Siva S; Brabrand S; Dirix P; Liefhooghe N; Otte FX; Gomez-Iturriaga A; Everaerts W; Shelan M; Conde-Moreno A; López Campos F; Papachristofilou A; Guckenberger M; Scorsetti M; Zapatero A; Villafranca Iturre AE; Eito C; Couñago F; Muto P; Van De Voorde L; Mach N; Bultijnck R; Fonteyne V; Moon D; Thon K; Mercier C; Achard V; Stellamans K; Goetghebeur E; Reynders D; Zilli T
Eur Urol Oncol; 2024 Jun; 7(3):462-468. PubMed ID: 37821242
[TBL] [Abstract][Full Text] [Related]
12. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.
De Bruycker A; De Bleser E; Decaestecker K; Fonteyne V; Lumen N; De Visschere P; De Man K; Delrue L; Lambert B; Ost P
Eur Urol; 2019 May; 75(5):826-833. PubMed ID: 30503072
[TBL] [Abstract][Full Text] [Related]
13. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.
Achard V; Jaccard M; Vanhoutte F; Siva S; Heikkilä R; Dirix P; Liefhooghe N; Otte FX; Gomez-Iturriaga A; Berghen C; Shelan M; Conde-Moreno A; López Campos F; Papachristofilou A; Guckenberger M; Meersschout S; Putora PM; Zwahlen D; Couñago F; Scorsetti M; Eito C; Barrado M; Zapatero A; Muto P; Van De Voorde L; Lamanna G; Koutsouvelis N; Dipasquale G; Ost P; Zilli T
Radiother Oncol; 2022 Jul; 172():1-9. PubMed ID: 35476942
[TBL] [Abstract][Full Text] [Related]
14. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.
Nicosia L; Franzese C; Mazzola R; Franceschini D; Rigo M; D'agostino G; Corradini S; Alongi F; Scorsetti M
Strahlenther Onkol; 2020 Mar; 196(3):213-221. PubMed ID: 31559480
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice.
Panje C; Zilli T; Dal Pra A; Arnold W; Brouwer K; Garcia Schüler HI; Gomez S; Herrera F; Khanfir K; Papachristofilou A; Pesce G; Reuter C; Vees H; Zwahlen D; Putora PM
Radiat Oncol; 2019 Oct; 14(1):177. PubMed ID: 31619296
[TBL] [Abstract][Full Text] [Related]
16. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.
Jereczek-Fossa BA; Fanetti G; Fodor C; Ciardo D; Santoro L; Francia CM; Muto M; Surgo A; Zerini D; Marvaso G; Timon G; Romanelli P; Rondi E; Comi S; Cattani F; Golino F; Mazza S; Matei DV; Ferro M; Musi G; Nolè F; de Cobelli O; Ost P; Orecchia R
Clin Genitourin Cancer; 2017 Aug; 15(4):e623-e632. PubMed ID: 28185875
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy of oligometastatic prostate cancer: a systematic review.
Rogowski P; Roach M; Schmidt-Hegemann NS; Trapp C; von Bestenbostel R; Shi R; Buchner A; Stief C; Belka C; Li M
Radiat Oncol; 2021 Mar; 16(1):50. PubMed ID: 33750437
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience.
Oehler C; Zimmermann M; Adam L; Curschmann J; Sumila M; Strebel RT; Cathomas R; Li Q; Schneider U; Zwahlen DR
BMC Urol; 2019 Sep; 19(1):84. PubMed ID: 31500621
[TBL] [Abstract][Full Text] [Related]
20. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.
Huynh MA; Tang C; Siva S; Berlin A; Hannan R; Warner A; Koontz B; De Meeleer G; Palma D; Ost P; Tran PT
Eur Urol Oncol; 2023 Feb; 6(1):28-38. PubMed ID: 36283936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
